35 Recruiting Studies Using Mosunetuzumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Mosunetuzumab
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
📍 City of Hope Cancer Center — Duarte, California
Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Relapsed or Refractory Follicular Lymphoma
View Study & Checklist ➔A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
📍 Infirmary Cancer Care — Mobile, Alabama
Non-Hodgkin Lymphoma
View Study & Checklist ➔Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
📍 Weill Cornell Medicine/NewYork-Presbyterian Hospital — New York, New York
Follicular Lymphoma
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
📍 University of Alabama at Birmingham School of Medicine — Birmingham, Alabama
B-cell Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
📍 City of Hope National Medical Center — Duarte, California
Follicular Lymphoma
View Study & Checklist ➔Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
📍 Washington University School of Medicine — St Louis, Missouri
Lymphoma, Follicular
View Study & Checklist ➔A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
📍 University of California San Francisco - Fresno Center for Medical Education and Research — Clovis, California
B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
📍 Washington University School of Medicine — St Louis, Missouri
B Cell Lymphoma
View Study & Checklist ➔Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
📍 Washington University School of Medicine — St Louis, Missouri
Large B-cell Lymphoma
View Study & Checklist ➔Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
📍 Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Waldenstrom Macroglobulinemia
View Study & Checklist ➔Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
📍 Yale Cancer Center — New Haven, Connecticut
Follicular Lymphoma
View Study & Checklist ➔Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
📍 University of Miami — Miami, Florida
Extranodal Marginal Zone Lymphoma
View Study & Checklist ➔Mosunetuzumab for CLL MRD Clearance
📍 Brigham & Women's Hospital — Boston, Massachusetts
Leukemia
View Study & Checklist ➔CAR-T Followed by Bispecific Antibodies
📍 University of Nebraska Medical Center — Omaha, Nebraska
Large B-cell Lymphoma
View Study & Checklist ➔A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
📍 Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
Relapsed/Refractory Non-Hodgkin Lymphoma
View Study & Checklist ➔Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
View Study & Checklist ➔Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Grade 1 Follicular Lymphoma
View Study & Checklist ➔A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
📍 Mayo Clinic Rochester — Rochester, Minnesota
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
View Study & Checklist ➔Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Diffuse Large B Cell Lymphoma (DLBCL)
View Study & Checklist ➔A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
📍 Wilmot Cancer Institute — Rochester, New York
Diffuse Large B-Cell Lymphoma (DLBCL)
View Study & Checklist ➔A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
📍 Georgetown University (Data Collection Only) — Washington D.C., District of Columbia
Follicular Lymphoma
View Study & Checklist ➔A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
📍 Clnica SER da Bahia — Salvador, Estado de Bahia
Lupus
View Study & Checklist ➔Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Classic Follicular Lymphoma
View Study & Checklist ➔A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
📍 Mayo Clinic Phoenix — Phoenix, Arizona
B-cell Malignancy
View Study & Checklist ➔Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
📍 UT MD Anderson — Houston, Texas
Lymphocytic Leukemia
View Study & Checklist ➔CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
📍 University of Miami — Miami, Florida
Refractory Non-Hodgkin Lymphoma
View Study & Checklist ➔A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
📍 M D Anderson Cancer Center — Houston, Texas
Hodgkin Lymphoma
View Study & Checklist ➔Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Recurrent Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Ann Arbor Stage II Follicular Lymphoma
View Study & Checklist ➔Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Nodular Lymphocyte Predominant B-Cell Lymphoma
View Study & Checklist ➔Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
📍 OHSU Knight Cancer Institute — Portland, Oregon
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
📍 City of Hope Medical Center — Duarte, California
Recurrent Grade 1 Follicular Lymphoma
View Study & Checklist ➔A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
📍 MD Anderson Cancer Center — Houston, Texas
Lymphoma
View Study & Checklist ➔